

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/018,938 #3
9-25-02 KAY
attachment

Attorney Docket No.: PENN-0794
Inventors: Eberwine et al.
Serial No.: 10/018,938
Filing Date: December 20, 2001
Examiner: Not Yet Assigned
Group Art Unit: Not Yet Assigned
Title: Molecular Correlates of Schizophrenia
and Methods of Diagnosing Schizophrenia
via these Molecular Correlates

"Express Mail" Label No. EV124972082US
Date of Deposit June 21, 2002

I hereby certify that this paper is being deposited with the
United States Postal Service "Express Mail Post Office
to Addressee" service under 37 CFR 1.10 on the date
indicated above and is addressed to the U.S. Patent and Trademark
Office, Box PCT, Post Office Box 2327, Arlington, VA 22202

By Jane Massey Licata
Typed Name: Jane Massey Licata, Reg. No. 32,257

U.S. Patent and Trademark Office
Box 2327
Arlington, VA 22202

Sir:

INFORMATION DISCLOSURE STATEMENT

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

(XX) In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three

months of the filing date of the above-identified application, within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, no additional fee is required.

() In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, therefore:

() Certification in Accordance with §1.97(e) is set forth below; or

() The fee of \$180.00 as set forth in §1.17(p) is attached.

() In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee, therefore included are: Certification in Accordance with §1.97(e); Petition Requesting Consideration of the Information Disclosure Statement; and the fee of \$130.00 as set forth in §1.17(i)(1).

(xx) Copies of each of the references listed on the attached Form PTO-1449 (modified) are enclosed herewith.

() In accordance with §1.98(d), copies of some or all of the references listed on the attached Form PTO-1449 (modified) are not enclosed herewith because they were previously submitted to the U.S. Patent and Trademark Office in prior application Serial No. _____, filed _____, for which a claim for priority under 35 U.S.C. §120 has been made in the instant application.

Please charge any deficiency or credit any overpayment to Deposit Account No. 50-1619. This form is submitted in duplicate.

() The relevance of the listed references in a foreign language is as stated in the specification at pages @@.

(~~xx~~) All listed references are in the English language.

Respectfully submitted,

Jane Massey Licata

Jane Massey Licata
Registration No. 32,257

Date: June 21, 2002

Licata & Tyrrell P.C.
66 E. Main Street
Marlton, New Jersey 08053

(856) 810-1515

Form PTO-1449 Modified List of Patents and Publications Cited by Applicant (Use several sheets if necessary) U.S. Department of Commerce		Docket No. PENN-0794	Serial No. 10/018,938
		Applicant Eberwine et al.	
		Filing Date December 20, 2001	Group Not Yet Assigned
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)			
	AA	Eastwood et al., "Hippocampal and Cortical Growth-Associated Protein-43 Messenger RNA in Schizophrenia", Neuroscience 1998 86(2):437-448	
	AB	Glantz et al., "Reduction of Synaptophysin Immunoreactivity in the Prefrontal Cortex of Subjects with Schizophrenia" Arch Gen Psychiatry 1997 54:943-952	
	AC	Sokolov B.P., "Expression of NMDAR1, GluR1, GluR7, and KA1 Glutamate Receptor mRNAs Is Decreased in Frontal Cortex of "Neuroleptic-Free" Schizophrenics: Evidence on Reversible Up-Regulation by Typical Neuroleptics", J. Neurochemistry 1998 2454-2463	
EXAMINER		DATE CONSIDERED	